美国 · SEC FORM 4
CV Sciences, Inc.
CVSI · OTC · CIK 0001510964 · Healthcare · Drug Manufacturers—Specialty & Generic
内部人信号
1 位买方 · 10 条买入交易行 · $114.8K 买入总额
为什么有这个信号?
评分构成
每条进度条表示其对当前分数的贡献;权重和公式保持不变。
哪些因素限制了当前分数?
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ⚠ 角色得分低 · 买入者中职位最高的是:TenPercentOwner(CEO、董事长和持股 10% 以上的股东得分最低)
- ⚠ Purchase activity is becoming less recent
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后,不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 42.5
- 42.3
- 42.3
- 42.2
- 42.1
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息,不影响内部人信号。
价格表现
- 1M
- -50.0%
- 3M
- -50.0%
- 6M
- -75.0%
- 12M
- -75.0%
波动率与流动性
- 波动率
- 227.8%
- Beta
- —
- 平均每日成交额
- USD 5,553
估值
- 市值
- USD 2.3M
- P/E
- —
基本面
- 利润率
- -6.9%
- ROE
- -65.3%
- 细分行业
- Drug Manufacturers—Specialty & Generic
市场数据
价格数据截至:2026-10-11 · 价格来源:OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件:市值, 利润率, ROE · 财年截止日:2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期:2026-08-11 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 14,190
- 上期报告
- 6,360
- 日均成交量
- 1,839,462
- 回补天数
- ≤ 1.0
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-07 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 94,854 | USD 0.02 | USD 1,897 | SEC 申报 ↗ |
| 2026-08-04 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 108,000 | USD 0.02 | USD 2,160 | SEC 申报 ↗ |
| 2026-07-31 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 1,730,000 | USD 0.02 | USD 34,600 | SEC 申报 ↗ |
| 2026-07-29 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 60,000 | USD 0.02 | USD 1,200 | SEC 申报 ↗ |
| 2026-07-28 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 1,830,000 | USD 0.02 | USD 36,600 | SEC 申报 ↗ |
| 2026-07-24 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 470,075 | USD 0.02 | USD 9,402 | SEC 申报 ↗ |
| 2026-07-22 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 272,500 | USD 0.02 | USD 5,450 | SEC 申报 ↗ |
| 2026-07-21 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 335,000 | USD 0.02 | USD 6,700 | SEC 申报 ↗ |
| 2026-07-17 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 749,000 | USD 0.02 | USD 14,980 | SEC 申报 ↗ |
| 2026-07-16 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 91,387 | USD 0.02 | USD 1,828 | SEC 申报 ↗ |
| 2021-05-21 | MAROON JOSEPH C MD | 买入 (P) | Common Stock | 50,000 | USD 0.38 | USD 19,000 | SEC 申报 ↗ |
| 2020-05-14 | BLAKE PAUL | 买入 (P) | Common Stock | 12,801 | USD 0.39 | USD 4,992 | SEC 申报 ↗ |
| 2020-02-06 | MAROON JOSEPH C MD | 买入 (P) | Common Stock | 26,000 | USD 0.94 | USD 24,440 | SEC 申报 ↗ |
Form 4 申报证据
10 transaction lines in the latest 365-day window; 47 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-07 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 94,854 | USD 0.02 | USD 1,897 | SEC 申报 ↗ |
| 2026-08-04 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 108,000 | USD 0.02 | USD 2,160 | SEC 申报 ↗ |
| 2026-07-31 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 1,730,000 | USD 0.02 | USD 34,600 | SEC 申报 ↗ |
展开近期 Form 4 证据 (10 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-07 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 94,854 | USD 0.02 | USD 1,897 | SEC 申报 ↗ |
| 2026-08-04 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 108,000 | USD 0.02 | USD 2,160 | SEC 申报 ↗ |
| 2026-07-31 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 1,730,000 | USD 0.02 | USD 34,600 | SEC 申报 ↗ |
| 2026-07-29 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 60,000 | USD 0.02 | USD 1,200 | SEC 申报 ↗ |
| 2026-07-28 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 1,830,000 | USD 0.02 | USD 36,600 | SEC 申报 ↗ |
| 2026-07-24 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 470,075 | USD 0.02 | USD 9,402 | SEC 申报 ↗ |
| 2026-07-22 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 272,500 | USD 0.02 | USD 5,450 | SEC 申报 ↗ |
| 2026-07-21 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 335,000 | USD 0.02 | USD 6,700 | SEC 申报 ↗ |
| 2026-07-17 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 749,000 | USD 0.02 | USD 14,980 | SEC 申报 ↗ |
| 2026-07-16 | CHEEVER CHARLIE E III | 买入 (P) | Common Stock, $0.0001 par value per share | 91,387 | USD 0.02 | USD 1,828 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | CVSI |
| CIK | 0001510964 |
| 行业 | Healthcare |
| 细分行业 | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | OTC |
数据覆盖
| 本地 Form 4 历史 | 47 transaction lines from 2020-01-07 to 2026-08-07 13 P purchase lines · 34 S sale lines · 0 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.